Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com - Cantor Fitzgerald has reiterated its Overweight rating on aTyr Pharma (NASDAQ:ATYR) following meetings with the company’s management last week, according to a research note published Monday. The stock, which has seen a 157% return over the past year despite a recent 24% weekly decline, currently trades at $4.85. According to InvestingPro data, analyst targets range from $9 to $35 per share.
The firm’s analyst noted that investor discussions centered on details of aTyr’s Phase 3 trial for Efzofitimod, an NRP2 modulator being tested for Pulmonary Sarcoidosis (PS). Topline results from this pivotal trial are expected in early-to-mid September, with detailed data presentation scheduled for the European Respiratory Society conference later that month. With earnings scheduled for August 13 and maintaining a "Fair" overall financial health score according to InvestingPro, investors have multiple near-term catalysts to monitor.
Cantor Fitzgerald indicated that aTyr appears to have executed the trial effectively, with management observing separation in patient performance based on blinded data. This suggests either the drug is working or that pulmonary sarcoidosis patients have historically received higher-than-necessary steroid treatments.
The research firm estimates significant potential upside of $15-$20 per share (200-300%) if the Phase 3 trial yields positive results, depending on the strength of the data. Conversely, Cantor projects downside risk of less than $1 per share (80-90% decline) should the trial fail.
aTyr’s Efzofitimod is being developed as a potential first-in-class therapy for patients with pulmonary sarcoidosis, a rare inflammatory disease affecting the lungs.
In other recent news, aTyr Pharma announced the completion of its pivotal Phase 3 EFZO-FIT study, which evaluated efzofitimod for pulmonary sarcoidosis. This development has led H.C. Wainwright to reiterate its Buy rating and maintain a $35 price target. Additionally, Leerink Partners continues to hold an Outperform rating with a $16 price target, highlighting management’s optimism about the upcoming Phase 3 readout for efzofitimod. Meanwhile, aTyr Pharma is set to join the Russell 2000 and Russell 3000 indexes, effective after market close on June 27, 2025. The inclusion in these indexes marks a significant milestone for the company.
Furthermore, H.C. Wainwright reaffirmed its Buy rating on aTyr Pharma following interim results from the ongoing Phase 2 EFZO-CONNECT study, which showed promising outcomes for systemic sclerosis-related interstitial lung disease (SSc-ILD). The interim analysis of this study reported clinically significant improvements in three out of four patients with diffuse SSc-ILD. The study’s findings are based on the modified Rodnan Skin Score, which indicated stable or improved scores in all participants. These developments underscore aTyr Pharma’s progress in advancing its therapeutic candidate, efzofitimod, across multiple indications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.